Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

NSCLC (Non-small Cell Lung Cancer) Clinical Trials

6 recruiting trials for NSCLC (Non-small Cell Lung Cancer). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
0
Phase 3 Trials
6
Sponsors

Recruiting Trials

RECRUITINGNCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a...

Sponsor: ElephasEnrolling: 20008 locations
RECRUITINGPhase 1NCT07376707

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic...

This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in...

Sponsor: Hefei TG ImmunoPharma Co., Ltd.Enrolling: 1941 location
RECRUITINGNCT06605404

Pan-tumor MRD Study

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage...

Sponsor: Paradigm HealthEnrolling: 13502 locations
RECRUITINGPhase 1 / Phase 2NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 24010 locations
RECRUITINGPhase 1NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid...

Sponsor: Nuvectis Pharma, Inc.Enrolling: 14012 locations
RECRUITINGPhase 1NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with...

Sponsor: Iambic Therapeutics, IncEnrolling: 24320 locations